Oct 10th 2012 - Edison Investment Research today published a report on Cytori Therapeutics entitled "Ex-STEMI-nate". In summary, the report says:
Cytori is developing a diverse set of indications for use with its Celution system with the next advance a pivotal 216 patient trial to establish the use of adipose cells to aid recovery after a STEMI heart attack. Current share price support comes from the US Phase II ATHENA trial in chronic heart disease, a massive potential market. Cytori has promising developments in wound healing. Cell products for breast and buttock reconstruction and augmentation had EU sales of $8m in 2011.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
